RXPA 380

• Description :

  RXPA 380 is a C-terminal specific angiotensin-converting enzyme (ACE) inhibitor with a Ki of 3 nM. RXPA 380 inhibits C-domain mutants of human recombinant ACE with an IC50 of 2.5 nM[1].

• UNSPSC :

  12352005

• Target :

  Angiotensin-converting Enzyme (ACE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/rxpa-380.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(O)[C@H](CC1=CNC2=CC=CC=C12)NC(C3C(P([C@@H](NC(OCC4=CC=CC=C4)=O)CC5=CC=CC=C5)(O)=O)CCC3)=O

• Molecular Formula :

  C33H36N3O7P

• Molecular Weight :

  617.63

• References & Citations :

  [1]Georgiadis D, et al. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res. 2003 Jul 25;93 (2) :148-54.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [564479-79-4]